MolecuLight® improves success with
Outcomes & Cost Effectiveness

RCT evidence that MolecuLight imaging dramatically improved DFU healing outcomes. Wound healing rates doubled at 12-weeks (45% vs. 22%) and the presence/absence of bacterial fluorescence reliably predicted the degree of wound closure.

A retrospective review across 55 long-term care facilities showing that MolecuLight significantly improved pressure injury outcomes compared to standard care alone. Patients treated with MolecuLight experienced a 71% higher healing rate, healed 28% faster, were 1.4 to 1.8 times more likely to heal, and experienced 75% fewer complications.

A “before and after” cohort study showing that fluorescence imaging reduced antibiotic and antimicrobial dressing needs and wound care costs while improving foot ulcer healing rates (39% to 48%).

Fluorescence imaging predicted wound area reduction based on bacterial presence, with persistent bacterial loads correlating to worse outcomes. MolecuLight digital wound measurements were significantly more accurate than manual measurements (23% overestimation with ruler).

MolecuLight imaging prevented the need for intravenous antibiotics and hospitalization in 100% of wound-related cellulitis cases by aiding in early diagnosis and bacterial source control.

MolecuLight imaging provided real-time guidance for debridement and antibiotic selection in chronic lower extremity wounds. Removal of bacterial fluorescence signals was associated with reduced wound areas.